意昂2官网,意昂平台2

• Hainan Poly Pharm was Founded

• Poly Launched its First Product Nimodipine Capsules to Market

• Zhejiang Poly Pharm was Established

• cGMP Certification Launched to Start a New Journey of Internationalization

• Production Line of Ganciclovir Sodium for Injection and its API Passed WHO on-site GMP Inspection

• 1. Hainan Poly Pharm Changed to be a Joint-stock Company；

• 2. Production Line of Ganciclovir Sodium for Injection and its API Passed EU EMA On-site GMP Inspection；

• 3. Product Approved to WHO pre-qualification Program

• Ganciclovir sodium for injection receives EU marketing authorization

• Production Line of Lyophilized Powder Injection Passed US FDA Inspection

• EU Marketing Authorization Obtained for Levetiracetam Injection

• Poly Pharma Successfully Listed in Growth Enterprise Board

1. Facility of Hangzhou Poly Pharm Put into Operation；

2. New Injection Building and Upgraded API Workshop of Hainan Poly Pharm Put into Operation；

3. API Workshop and Lyophilized Injection Line Passed WHO GMP Follow-up Inspection

Anhui Poly Pharm Laid Foundation Stone for its Manufacturing Facility

1. First Shippment of Sodium Nitroprusside Injection to the United States；

2. Bivalirudin for Injection Approved for Marketing in China；

3. Ganciclovir Sodium for Injection Passed Consistency evalsuation.

1. Zhejiang Poly Pharm received EIR for its first pre-approval inspection by FDA

2. Beijing Pharmaceutical Innovation Platform was jointly established by Institute of High Energy Physics (Chinese Academy of Sciences) and Poly Pharm.

3. Poly Pharma Steps into DNA Vaccine；

4. Anqing facility officially start production。

1、Celebrating 30th Anniversary of Poly Pharm Group (1992-2020)；

2、Initial Shippment of Esomeprazole Sodium for Injection to the United States；

3、Sodium Nitroprusside Injection passed the evalsuation of bio-equivalence consisteny and approved for marketing in China.